All In Biotech

Drug Trial Radar · NCT06967831

Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells

Using iPSC Derived Human Basal Ganglia Neurons From Patients With Leigh Syndrome for Metabolic Studies, Assay Development, and Drug Repurposing.

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 1, 2020

Primary completion

Feb 28, 2030

Study completion Feb 28, 2030

Sponsor

Lead sponsor
Charite University, Berlin, GermanyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Union; German Research Foundation; German Federal Ministry of Education and Research
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this project, the investigators are using iPSC lines derived from patients with Leigh syndrome that carry mutations in the mitochondrial (mtDNA) and in the nuclear DNA (nDNA) to reprogram them into neural progenitor cells and into dopaminergic neurons. The researchers are using this experimental system to screen FDA (Food and Drug Administration, USA) and EMA (European Medicines Agency) approved drugs for a positive effect on Leigh patient-derived neuronal cells (drug repurposing) using various biochemical, optic, and morphological outcome measures. Confirmed positive hits may be used for compassionate off-label use in Leigh patients when no standard treatment is available.

Conditions

  • Leigh Syndrome (Maternally Inherited, MILS)
  • Leigh Syndrome (AR, AD, XR)

Interventions

  • skin biopsyProcedure

    Taking a punch skin biopsy of 3 mm diameter under local anesthesia and culturing skin fibroblasts from them.

  • generation of iPSCsOther

    Using cultured skin fibroblasts of the patients, iPSCs will be generated according to standard procedures.

  • blood drawingDiagnostic test

    Drawing blood from a peripheral vein for DNA and RNA isolation. The degree of heteroplasmy (mutation load) for the mtDNA mutation will be determined in the blood DNA.

  • off-label compassionate drug useDrug

    In case the investigators identify a positive hit during drug repurposing with FDA and EMA approved substances, they will offer it as off-label compassionate use to patients for whom no standard treatment is available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of the increased mitochondrial membrane potentialTime frame: 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Düsseldorf

    Düsseldorf, North Rhine-Westphalia, Germany · Recruiting

  • Charite - Universtaetsmedizin Berlin

    Berlin, State of Berlin, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.